Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

8301	Companies
115073	Keywords
55422	Articles
62513	Press releases

Home
Companies
Biophytis

PRESS RELEASE

published on 06/20/2024 at 01:10, 5 months 1 day ago

Biophytis extends its contract with Atlas to secure financing for its business activities
Biophytis extends financing agreement with Atlas, ensures funding for clinical programs OBA in obesity and MYODA in DMD. Details on the contract amendment and risk factors

Biophytis Atlas Financing Agreement Clinical Programs Risk Factors
BRIEF

published on 06/19/2024 at 23:05, 5 months 1 day ago

Biophytis Extends Financing Contract with Atlas

Biophytis Biotechnology Financing Clinical Trials Atlas
REGULATED PRESS RELEASE

published on 06/19/2024 at 23:00, 5 months 1 day ago

Biophytis extends its contract with Atlas to secure financing for its business activities
Biophytis extends bond financing agreement with Atlas, securing funding for clinical programs in obesity and Duchenne Muscular Dystrophy. Terms reflect confidence in growth potential

Biophytis Atlas Growth Potential Clinical Programs Bond Financing Agreement
BRIEF

published on 06/12/2024 at 10:16, 5 months 9 days ago

Biophytis announces the success of the industrial transfer of production of BIO101

Biophytis Biotechnology Duchenne Muscular Dystrophy BIO101 Seqens
PRESS RELEASE

published on 06/12/2024 at 10:11, 5 months 9 days ago

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis successfully transfers BIO101 (20-hydroxyecdysone) production to industrial scale with Seqens, enhancing therapeutic solutions for Duchenne Muscular Dystrophy patients

Biophytis Duchenne Muscular Dystrophy BIO101 Seqens 20-hydroxyecdysone
BRIEF

published on 06/12/2024 at 07:05, 5 months 9 days ago

Biophytis Announces Successful Industrial Transfer of BIO101 Production by Seqens

Biophytis Clinical Trial Duchenne Muscular Dystrophy BIO101 Seqens
REGULATED PRESS RELEASE

published on 06/12/2024 at 07:00, 5 months 9 days ago

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis announces successful industrial transfer of BIO101 (20-hydroxyecdysone) production by Seqens for DMD treatment. Collaboration strengthens therapeutic solutions and accelerates clinical programs

Biophytis Clinical Development Duchenne Muscular Dystrophy BIO101 Seqens
BRIEF

published on 06/10/2024 at 08:23, 5 months 11 days ago

Biophytis Files IND Application for Phase 2 Obesity Study with US FDA

FDA Biophytis Clinical Study Obesity IND Application
BRIEF

published on 06/10/2024 at 08:21, 5 months 11 days ago

Biophytis files IND application for phase 2 study in obesity

FDA Biophytis Phase 2 BIO101 Obesity
REGULATED PRESS RELEASE

published on 06/10/2024 at 08:18, 5 months 11 days ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis files IND application with US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone) to assess muscle strength improvement in lower limbs and secondary endpoints like mobility and body composition

FDA Biophytis BIO101 IND Application Obesity Study

Accesswire

Published on 11/21/2024 at 17:35, 1 hour 25 minutes ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 1 hour 30 minutes ago

SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 2 hours 30 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 2 hours 59 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 3 hours ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 18:36, 24 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 1 hour 2 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 1 hour 8 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 1 hour 9 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 16:00, 3 hours ago

Director/PDMR Shareholding

Les Echos

Published on 11/21/2024 at 06:58, 12 hours 2 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 23 hours 40 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 1 hour ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 1 hour ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 11 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE